HK1255313A1 - 含有培美曲塞或其药学上可接受的盐的稳定药物组合物 - Google Patents

含有培美曲塞或其药学上可接受的盐的稳定药物组合物 Download PDF

Info

Publication number
HK1255313A1
HK1255313A1 HK18114448.9A HK18114448A HK1255313A1 HK 1255313 A1 HK1255313 A1 HK 1255313A1 HK 18114448 A HK18114448 A HK 18114448A HK 1255313 A1 HK1255313 A1 HK 1255313A1
Authority
HK
Hong Kong
Prior art keywords
pemetrexed
stability
monothioglycerol
antioxidant
composition
Prior art date
Application number
HK18114448.9A
Other languages
English (en)
Chinese (zh)
Inventor
周珉載
周珉载
徐惠珍
朴信政
Original Assignee
株式会社钟根堂
株式會社鐘根堂
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社钟根堂, 株式會社鐘根堂 filed Critical 株式会社钟根堂
Publication of HK1255313A1 publication Critical patent/HK1255313A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK18114448.9A 2015-12-14 2016-12-13 含有培美曲塞或其药学上可接受的盐的稳定药物组合物 HK1255313A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2015-0178339 2015-12-14
KR1020150178339A KR101693675B1 (ko) 2015-12-14 2015-12-14 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물
PCT/KR2016/014594 WO2017105059A1 (ko) 2015-12-14 2016-12-13 페메트렉시드 또는 그의 약제학적으로 허용가능한 염을 함유하는 안정화된 약학조성물

Publications (1)

Publication Number Publication Date
HK1255313A1 true HK1255313A1 (zh) 2019-08-16

Family

ID=57832487

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114448.9A HK1255313A1 (zh) 2015-12-14 2016-12-13 含有培美曲塞或其药学上可接受的盐的稳定药物组合物

Country Status (9)

Country Link
US (1) US10792285B2 (enExample)
EP (1) EP3391908A4 (enExample)
JP (3) JP2019502751A (enExample)
KR (1) KR101693675B1 (enExample)
CN (1) CN108463251A (enExample)
HK (1) HK1255313A1 (enExample)
MY (1) MY191043A (enExample)
PH (1) PH12018501274A1 (enExample)
WO (1) WO2017105059A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019244965A1 (ja) * 2018-06-20 2019-12-26 日本化薬株式会社 ペメトレキセドナトリウム注射用溶液製剤、並びにその製造方法
CN116474218A (zh) * 2019-06-28 2023-07-25 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
JP2025511651A (ja) * 2022-06-09 2025-04-16 上海雲晟研新生物科技有限公司 ペメトレキセド二ナトリウム液体組成物、その製造方法及び応用
JP2024006619A (ja) 2022-07-04 2024-01-17 セイコーエプソン株式会社 印刷装置、情報処理装置、情報処理システム、処理方法、及び、プログラム

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0162654B1 (ko) 1989-12-11 1998-11-16 알렌 제이. 시니스갤리 N-(피롤로[2,3-d]피리미딘-3-일아크릴)-글루타민산 유도체
US6686365B2 (en) 2000-02-04 2004-02-03 Eli Lilly And Company Pharmaceutical composition
MXPA02007191A (es) * 2000-02-04 2002-12-09 Lilly Co Eli Composicion farmaceutica que comprende permetrexed junto con monotioglicerol, l-cisteina o acido tioglicolico.
JP2013540104A (ja) * 2010-07-28 2013-10-31 イーグル・ファーマシューティカルズ・インコーポレーテッド 延長された保存安定性を有するペメトレキセドを含有する医薬組成物
KR20130122065A (ko) 2012-04-30 2013-11-07 씨제이제일제당 (주) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
EP2666463A1 (en) * 2012-05-21 2013-11-27 Synthon BV Stabilized liquid composition comprising pemetrexed
PT2854768T (pt) * 2012-05-30 2017-05-19 Fresenius Kabi Oncology Ltd Composições farmacêuticas de pemetrexed
DE102012010774A1 (de) * 2012-05-31 2013-12-05 Stada Arzneimittel Ag Pharmazeutische Pemetrexed-Lösung
KR101260636B1 (ko) 2012-11-29 2013-05-13 씨제이제일제당 (주) 안정화된 페메트렉시드 제제
KR101485243B1 (ko) * 2013-05-08 2015-01-21 씨제이헬스케어 주식회사 안정화된 페메트렉시드 제제
JP6094388B2 (ja) * 2013-06-07 2017-03-15 ニプロ株式会社 ペメトレキセドを含む注射用組成物
EP3040074B1 (en) * 2013-10-03 2018-07-25 Fujifilm Corporation Injection preparation and method for producing same
JP6099557B2 (ja) * 2013-12-27 2017-03-22 富士フイルム株式会社 注射液製剤及びその製造方法
KR101574875B1 (ko) * 2014-02-13 2015-12-04 건양대학교산학협력단 안정화된 페니실린 복합 현탁 제제
PL3124026T3 (pl) * 2014-03-28 2019-03-29 Fujifilm Corporation Preparat iniekcyjny i sposób jego wytwarzania
US20170340639A1 (en) * 2015-03-26 2017-11-30 Ftf Pharma Private Limited Pharmaceutical composition of pemetrexed
KR101919436B1 (ko) * 2015-05-28 2018-11-16 주식회사 삼양바이오팜 안정화된 약학 조성물 및 그의 제조방법

Also Published As

Publication number Publication date
US20200261458A1 (en) 2020-08-20
PH12018501274A1 (en) 2019-02-04
MY191043A (en) 2022-05-30
US10792285B2 (en) 2020-10-06
EP3391908A1 (en) 2018-10-24
EP3391908A4 (en) 2019-08-07
CN108463251A (zh) 2018-08-28
JP2020125359A (ja) 2020-08-20
JP2019502751A (ja) 2019-01-31
JP2022107687A (ja) 2022-07-22
WO2017105059A1 (ko) 2017-06-22
KR101693675B1 (ko) 2017-01-06

Similar Documents

Publication Publication Date Title
US9629844B2 (en) Stabilized pemetrexed formulation
KR101260636B1 (ko) 안정화된 페메트렉시드 제제
JP2022107687A (ja) ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物
US20150073000A1 (en) Stable ready-to-use pharmaceutical composition of pemetrexed
KR101843613B1 (ko) 약제학적 페메트렉시드 액제
CN101500571A (zh) 稳定的冻干制剂
KR20130122065A (ko) 페메트렉시드를 함유하는 안정화된 주사용 액상 제제
EP3544584B1 (en) Pharmaceutical parenteral formulation containing carglumic acid
JPWO2008023807A1 (ja) 安定化された医薬組成物
EP2983649A1 (en) Pemetrexed formulation
JP2019502751A5 (enExample)
US20220151923A1 (en) Stable liquid compositions of pemetrexed
US12280053B2 (en) Stable, ready to use aqueous pharmaceutical composition of pemetrexed
JP6236165B2 (ja) ペメトレキセドまたはその薬学的に許容される塩を含有する安定な医薬組成物
KR20250153621A (ko) 안정성이 개선된 페메트렉시드를 포함하는 약제학적 제제
HK1212224B (en) A stabilized pemetrexed formulation